SJTUXHi001-A
General
Cell Line |
|
| hPSCreg name | SJTUXHi001-A |
| Cite as: | SJTUXHi001-A (RRID:CVCL_C0F8) |
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
IBKMOLi002-A (CACNA1D L271H iPCs) Donor's gene variants: CACNA1D Donor diseases: hyperinsulinemic hypoglycemia Autism Spectrum Disorder Muscle Hypotonia Primary hyperaldosteronism |
| Last update | 31st March 2022 |
| User feedback | |
Provider |
|
| Generator | Shanghai Xinhua Hospital (SJTUXH) |
External Databases |
|
| BioSamples | SAMEA11567036 |
| Cellosaurus | CVCL_C0F8 |
| Wikidata | Q112930396 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
External Databases (Donor) |
|
| BioSamples | SAMEA11567035 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Ethics Committee of Xinhua Hospital |
| Approval number | XHEC-C-2019-076 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Medium |
StemPro® hESC SFM
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Unknown |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Unknown |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Unknown |
Characterisation
Analysis of Undifferentiated Cells
Morphology pictures
Differentiation to 3 germ layers
Expression of pluripotent markers of OCT4 SOX2 NANOG and SSEA4
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
Normal, 46XX
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.